Literature DB >> 23370794

Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents.

O M Doyle1, S De Simoni, A J Schwarz, C Brittain, O G O'Daly, S C R Williams, M A Mehta.   

Abstract

Ketamine acts as an N-methyl-D-aspartate receptor antagonist and evokes psychotomimetic symptoms resembling schizophrenia in healthy humans. Imaging markers of acute ketamine challenge have the potential to provide a powerful assay of novel therapies for psychiatric illness, although to date this assay has not been fully validated in humans. Pharmacological magnetic resonance imaging (phMRI) was conducted in a randomized, placebo-controlled crossover design in healthy volunteers. The study comprised a control and three ketamine infusion sessions, two of which included pretreatment with lamotrigine or risperidone, compounds hypothesized to reduce ketamine-induced glutamate release. The modulation of the ketamine phMRI response was investigated using univariate analysis of prespecified regions and a novel application of multivariate analysis across the whole-brain response. Lamotrigine and risperidone resulted in widespread attenuation of the ketamine-induced increases in signal, including the frontal and thalamic regions. A contrasting effect across both pretreatments was observed only in the subgenual prefrontal cortex, in which ketamine produced a reduction in signal. Multivariate techniques proved successful in both classifying ketamine from placebo (100%) and identifying the probability of scans belonging to the ketamine class (ketamine pretreated with placebo: 0.89). Following pretreatment, these predictive probabilities were reduced to 0.58 and 0.49 for lamotrigine and risperidone, respectively. We have provided clear demonstration of a ketamine phMRI response and its attenuation with both lamotrigine and risperidone. The analytical methodology used could be readily applied to investigate the mechanistic action of novel compounds relevant for psychiatric disorders such as schizophrenia and depression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23370794     DOI: 10.1124/jpet.112.201665

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  47 in total

1.  Modulatory effects of ketamine, risperidone and lamotrigine on resting brain perfusion in healthy human subjects.

Authors:  Sergey Shcherbinin; Orla Doyle; Fernando O Zelaya; Sara de Simoni; Mitul A Mehta; Adam J Schwarz
Journal:  Psychopharmacology (Berl)       Date:  2015-07-31       Impact factor: 4.530

Review 2.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

Review 3.  The role of machine learning in neuroimaging for drug discovery and development.

Authors:  Orla M Doyle; Mitul A Mehta; Michael J Brammer
Journal:  Psychopharmacology (Berl)       Date:  2015-05-28       Impact factor: 4.530

Review 4.  Biomarkers, designs, and interpretations of resting-state fMRI in translational pharmacological research: A review of state-of-the-Art, challenges, and opportunities for studying brain chemistry.

Authors:  Najmeh Khalili-Mahani; Serge A R B Rombouts; Matthias J P van Osch; Eugene P Duff; Felix Carbonell; Lisa D Nickerson; Lino Becerra; Albert Dahan; Alan C Evans; Jean-Paul Soucy; Richard Wise; Alex P Zijdenbos; Joop M van Gerven
Journal:  Hum Brain Mapp       Date:  2017-02-01       Impact factor: 5.038

5.  Metaplastic effects of subanesthetic ketamine on CA1 hippocampal function.

Authors:  Yukitoshi Izumi; Charles F Zorumski
Journal:  Neuropharmacology       Date:  2014-08-13       Impact factor: 5.250

6.  Dissociable effects of antipsychotics on ketamine-induced changes in regional oxygenation and inter-regional coherence of low frequency oxygen fluctuations in the rat.

Authors:  Jennifer Li; Keita Ishiwari; Michael W Conway; Jennifer Francois; John Huxter; John P Lowry; Adam J Schwarz; Mark Tricklebank; Gary Gilmour
Journal:  Neuropsychopharmacology       Date:  2014-01-20       Impact factor: 7.853

Review 7.  The effects of antiepileptic drugs on cognitive functional magnetic resonance imaging.

Authors:  Guilherme Coco Beltramini; Fernando Cendes; Clarissa Lin Yasuda
Journal:  Quant Imaging Med Surg       Date:  2015-04

8.  Effects of ketamine on brain function during response inhibition.

Authors:  M Steffens; C Neumann; A-M Kasparbauer; B Becker; B Weber; M A Mehta; R Hurlemann; U Ettinger
Journal:  Psychopharmacology (Berl)       Date:  2018-10-24       Impact factor: 4.530

Review 9.  Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.

Authors:  Marc S Lener; Mark J Niciu; Elizabeth D Ballard; Minkyung Park; Lawrence T Park; Allison C Nugent; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2016-05-12       Impact factor: 13.382

10.  Effects of ketamine on brain function during smooth pursuit eye movements.

Authors:  M Steffens; B Becker; C Neumann; A M Kasparbauer; I Meyhöfer; B Weber; M A Mehta; R Hurlemann; U Ettinger
Journal:  Hum Brain Mapp       Date:  2016-11       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.